Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b randomized double-blind placebo-controlled study of AZD0292 in bronchiectasis with chronic Pseudomonas aeruginosa colonization
MOH_2025-08-21_014289Phase 2Recruiting
- Sponsor
- AstraZeneca
- Start
- Aug 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of AZD-0292 in bronchiectasis and Pseudomonas aeruginosa airway colonization (3 arms), sponsored by AstraZeneca. Primary endpoints: Efficacy, Safety and 1 more. Started Aug 2025; status: recruiting.
02
Drugs
AZD-0292
03
Conditions
bronchiectasisPseudomonas aeruginosa airway colonization
Beyond the preview
Go deeper on MOH_2025-08-21_014289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-08-21_014289.